ABSTRACT-The effects of purinoceptor agonists on noradrenaline NA release by electrical stimulation in rat mesenteric arteries were examined to clarify the pharmacological properties of prejunctional purinoceptors on adrenergic nerves. Adenosine and the other P1-receptor agonists, 5'-(N-ethylcarboxamido) adenosine and 2-chloroadenosine, significantly inhibited the release of NA. Also b,g-methylene ATP and 2-methylthio ATP, P2-receptor agonists, significantly inhibited NA releases. The inhibitory effect of adenosine was significantly reduced by adenosine deaminase, but those of b,g-methylene ATP and 2-methylthio ATP were not affected. This suggests that the inhibitory effects of P2-receptor agonists are not due to conversion into adenosine. 1,3-Dipropyl-8-cyclopentylxanthine (DPCPX), a P1 (A1)-receptor antagonist, significantly reduced the inhibitory effects of not only the P1-but also P2-receptor agonists. Therefore, DPCPX appears to act on both prejunctional P1-and P2-receptor as an antagonist. Pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS), a P2-receptor antagonist, significantly reduced the inhibitory effects of the P2-receptor agonists, but not those of the P1-receptor agonists. From these findings in the rat mesenteric artery, the P1-receptor agonist-induced inhibition of NA-release appears to be mediated via a well-known prejunctional P1-receptor of the A1-subtype, but the P2-receptor agonist-induced inhibition appears to be mediated via an unidentified purinoceptor that is blocked not only by P2-receptor antagonists but also by P1-receptor antagonists.
Studies with a large number of adrenergic neuro-effector tissues containing both vascular and non-vascular tissues indicates that the prejunctional purinoceptor inhibits noradrenaline (NA) release (1) . It is generally accepted that this inhibitory purinoceptor is P1, or more specifically an A1-adenosine-receptor subtype, and a P 2-receptor agonist, such as ATP, exerts an inhibitory action via degradation to adenosine, a P1-receptor agonist (2 -4) . However, evidence is mounting that P2-receptor agonists also act prejunctionally to modulate NA release without conversion to adenosine (5 -10) . Giniatullin and Sokolova (11) have shown that ATP inhibits acetylcholine release at frog neuromuscular junctions, and this inhibition is blocked by suramin, P2-receptor antagonist, and a,b-methylene ATP which is known to be a desensitizing agent on P2 receptors, but not by a P1-receptor antagonist, 1,3-dipropyl-8-cyclopentylxanthine (DPCPX). Furthermore, a third subclass of purinoceptors that is not consistent with the P 1-or P2-receptor has been proposed in some tissues (6, 12 -14) . The common pharmacological properties of this unique purinoceptor shown in previous studies are as follows: a) this purinoceptor is activated by both P1-and P2-receptor agonists and b) this is blocked by alkylxanthines, P1-receptor antagonists. This unique purinoceptor was termed "hybrid" P 3-receptor (6) .
In the present study, the inhibitory effects of P2-receptor agonists on NA release was compared with those of P 1-receptor agonists to clarify the pharmacological properties of the prejunctional purinoceptor on sympathetic nerves in the rat mesenteric artery. A preliminary account of this study has been presented (15) .
MATERIALS AND METHODS

Tissue preparation
Male Wistar rats used in the present study were cared for 25 .0 mM NaHCO3 and 5.6 mM glucose. The solution was continually aerated with 95% O 2 and 5% CO2. Each artery was passed back and forth through a pair of platinum ring electrodes, 10-mm-apart, and then fixed as described previously (6) . A 60-min equilibration period was allowed for each artery.
Release experiment
After the equilibration period, electrical field stimulation (EFS) of the tissue was evoked by square wave pulses of 2-ms duration, at supramaximal voltage and a frequency of 2 Hz from a DPS-1100D stimulator (Dia Medical System Co., Ltd., Tokyo). Tissues were stimulated for 3 min, and then the bathing solution was rapidly removed by draining the organ chamber and the sample solution was processed for the determination of NA. A 3-min prestimulation sample was also collected before EFS. Tissues were stimulated twice at 30-min intervals, and these stimulation periods were designated S1 and S2. The influence of drugs on the EFS-evoked release of NA was assessed by exposing the tissue to tetrodotoxin, clonidine and purinergic antagonists for 3 min or to purinergic antagonists and adenosine deaminase for 30 min before the second stimulation (S2).
Measurement of noradrenaline
The sample collected from the organ chamber was immediately acidified to pH 2 with 0.4 ml of 0.4 M perchloric acid containing 1.3 mM Na 2EDTA and 5.3 mM Na2S2O5. The sample was then placed on ice after the addition of 0.1 ml of internal standard solution (10 ng/ ml 3,4-dihydroxybenzylamine). Catecholamines in the acidified samples were isolated using batch alumina chromatography and analyzed using high-performance liquid chromatography (HPLC)-electrochemical detection. Following the addition of 38 mg of alumina (Wako, Osaka) to each 2.5 ml acidified sample, the pH was adjusted to 8.6 with 0.9 ml of 1.5 M Tris-HCl (pH 9.0) containing 50 mM Na2EDTA. Samples were vortexed for 30 s and placed on a rotator in the cold for 15 min. The supernatant was discarded, and the alumina washed twice with 10 ml of double-distilled water before the catecholamines were eluted with 0.2 ml of 0.1 N HCl.
The HPLC-electrochemical detection system consisted of a solvent delivery system (LC-10AD; Shimadzu, Kyoto), a sample processor (AS-8020; Tosoh, Tokyo), an ODS column (CA-5 ODS; Eicom, Kyoto) and an electrochemical detector (ECD-300, Eicom) equipped with a glass carbon electrode (WG-CG, Eicom). The solvent system, which was pumped at a rate of 1.0 ml /min, consisted of 100 mM NaH2PO4, 0.54 mM Na2EDTA, 0.9 mM 1-octanesulfonate and 10% methanol (pH 3.8 with H 3PO4). The electrochemical detector was set at 0.6 V, which provided a NA detection limit of approximately 10 fmol.
The amount of NA present in each sample was calculated using the peak area ratios relative to the internal standard 3,4-dihydroxybenzyl amine as described previously (6) . In addition to the stimulation samples, 3-min prestimulation samples were also measured to calculate spontaneous NA release. EFS-evoked NA release; i.e., the difference between the amount of NA in the stimulation and prestimulation samples, is expressed as fmol /mg wet wt. of the tissue. Findings pertaining to the effects of agonists and antagonists on NA release are presented as the ratio of S2 to S1 determined in the absence (control) or presence of drugs at S2.
Materials
Adenosine, AMP, ADP, ATP, 2-chloroadenosine (2CA), 5'-(N-ethylcarboxamido)-adenosine (NECA), b,g-methylene ATP sodium salt (bgmATP), DPCPX and adenosine deaminase were all obtained from Sigma Chemical Co. (St. Louis, MO, USA). 2-methylthio ATP sodium salt (2mSATP) and 3,4-dihydroxybenzylamine hydrobromide were purchased from Aldrich Chem. Co. (Milwaukee, WI, USA). Other drugs used in this investigation, were pyridoxalphosphate-6-azophenyl-1-2',4'-disulphonic acid (PPADS; Tocris, Inc., Bristol, UK) and clonidine (Wako). All drugs, except DPCPX, were dissolved in distilled water before being diluted with Krebs solution. DPCPX were dissolved in dimethylsulfoxide (Nacalai Tesque, Inc., Kyoto).
Statistics
All values are presented as means with standard error (S.E.M.) for the individual groups. Statistical analysis of the data for the groups was carried out using Student's t-test and ANOVA followed by a post hoc test of Fisher's PLSD, where appropriate. A 0.05 level of probability was accepted as significant. In Table 1 , Pearson's correlation coefficient was used to assess the IC30. These statistical analyses were performed using a computer program (Stat View 4.5; Abacus Concepts, Inc., Berkeley, CA, USA).
RESULTS
Noradrenaline release
The amount of NA released from the mesenteric artery of rats in response to EFS at a set frequency of 2 Hz is shown in Fig. 1 . The release of NA at each of two stimulation periods (S1 and S2) in the absence of drugs was relatively constant, and the ratio of S2 / S1 was 1.07 ± 0.06 (n = 8). The EFS-evoked NA release was abolished by tetrodotoxin, a voltage-dependent sodium channel blocker, at 0.3 mM and significantly reduced by clonidine at 10 mM, an a2-adrenoceptor agonist (Fig. 1) .
Effects of P1-and P2-receptor agonists
As shown in Fig. 2 , ATP and its metabolites, ADP, AMP and adenosine, at 10 m M significantly inhibited the release of NA evoked by EFS to approximately 50% of the control, but did not affect the spontaneous NA release (data not shown). Figure 3 illustrates the concentration-inhibition curves for bgmATP, 2mSATP, 2CA and NECA. All four agonists produced a concentration-related inhibition of the release of NA, with maximum inhibition of the release being approximately 60% (the S2/ S1 value was about 0.4). From the findings presented in Fig. 3 , the concentration of each agonist that produced a 30% inhibition of NA release (i.e., the S2 /S1 value was approximately 0.7; IC 30) was calculated ( Table 1 ). The IC30 values were calculated using linear regression. The rank order of potency was Fig. 1 . Effects of tetrodotoxin (TTX, 0.3 mM) and clonidine (10 m M) on electrically evoked (2 Hz for 3 min) release of endogenous noradrenaline (NA) in the rat mesenteric artery. The mesenteric arteries were stimulated twice (S1 and S2) at 30-min intervals. Open and hatched columns indicate the amount of NA release (fmol /mg per 3 min) at S1 and S2, respectively. Each drug was added 3 min before the second stimulation period (S2). Each column represents a minimum of 4 experiments. **P<0.01 vs respective S1. Fig. 2 . Effects of ATP and its metabolites, ADP, AMP and adenosine (ADO), at 10 m M, on electrically evoked (2 Hz for 3 min) release of endogenous noradrenaline (NA) in the rat mesenteric artery. The mesenteric arteries were stimulated twice (S1 and S2) at 30-min intervals. Each purinoceptor agonist was added 3 min before the second stimulation period (S2). The effects of the agonists are presented as the ratio of the release of noradrenaline between the second (in the presence of agonist) and the first (in the absence of agonist) release period, i.e., the S2 /S1 ratio. Each column represents a minimum of 4 experiments. **P<0.01 vs control. Fig. 3 . The concentration-related effects of P1 purinoceptor agonists, 2-chloroadenosine (2CA, ) and 5'-N-ethylcarboxamido-adenosine (NECA, ), and P2 purinoceptor agonists, b ,g -methylene ATP (bgmATP, ) and 2-methylthio-ATP (2mSATP, ), on the electrically evoked (2 Hz for 3 min) release of endogenous noradrenaline (NA) in the rat mesenteric artery. The mesenteric arteries were stimulated twice (S1 and S2) at 30-min intervals. Each purinoceptor agonist was added 3 min before the second stimulation period (S2). The effects of the agonists are presented as the ratio of the release of noradrenaline between the second (in the presence of agonist) and the first (in the absence of agonist) release period, i.e., the S2 /S1 ratio. Abscissa indicates the concentration (log M) of the agonists. Each line represents a minimum of 4 experiments. *P<0.05, **P<0.01 vs control.
NECA > 2CA >bgmATP > 2mSATP. These P1-and P2-receptor agonists had no effect on spontaneous NA release (data not shown).
Effect of adenosine deaminase
To determine whether the inhibitory effects of P 2-receptor agonists on NA release were a direct presynaptic action by themselves or an indirect action via their metabolite adenosine, the effect of adenosine deaminase (0.3 U/ ml) on the inhibition of NA release by several purinoceptor agonists at 10 mM was examined. As shown in Fig. 4 , only the inhibitory effect of adenosine was reduced by adenosine deaminase, but the effects of bgmATP and 2mSATP were not significantly changed. Adenosine deaminase did not affect the EFS-evoked release of NA (data not shown).
Effect of a P1-receptor antagonist, DPCPX
The effect of the P1-receptor antagonist DPCPX at 0.1 m M on the release of NA and its interaction with purinoceptor agonists were investigated. DPCPX itself did not affect the EFS-evoked release of NA (data not shown), but antagonized the inhibitory effects of the P1-receptor agonists 2CA and NECA, at 10 m M each, as shown in Fig. 5 . DPCPX did antagonize the inhibitory effects of the P 2-receptor agonists bgmATP and 2mSATP, at 10 mM each, on the NA release. However, the inhibitory effect of clonidine at 10 mM was not affected by DPCPX at 0.1 mM (data not shown).
Effects of a P 2-receptor antagonist, PPADS
The effect of the P2-receptor antagonist PPADS at 1.0 mM on the release of NA and its interaction with purinoceptor agonists were investigated. PPADS alone did not affect the EFS-evoked release of NA from the mesenteric artery (data not shown). As shown in Fig. 6 , the drug antagonized the inhibitory effects of the P2-receptor agonists bgmATP and 2mSATP, at 10 m M each, but did not affect the inhibitory effects of the P1-receptor agonists 2CA and NECA, at 10 mM each.
DISCUSSION
In the present study, P2-receptor agonists, bgmATP and 2mSATP, inhibited the EFS-evoked NA release from the rat mesenteric artery, the action of which was not affected by adenosine deaminase at the concentration required to reduce the inhibitory action of adenosine. Therefore, these P2-receptor agonists appear to act directly to inhibit NA release without conversion to adenosine. This inhibition by the P2-receptor agonist was completely abolished by DPCPX, a P1-receptor antagonist. It is well known that xanthine derivatives penetrate into nerve cells and exhibit an inhibitory effect on phosphodiesterase followed by elevation of cAMP level (16) . Abrahamsen and Nedergaard (17) have suggested that cAMP positively participates in the excitation-release coupling of the nerve terminals. IshiiNozawa et al. (18) have shown that 8Br-cAMP, which is one type of cAMP analogue and is cell membrane permeable, enhances the EFS-evoked NA release without affecting spontaneous release. They also reported that forskolin, which activates adenylate cyclase via an interaction with the catalytic subunit of this enzyme (19, 20) , markedly enhanced the NA release from the rabbit ear artery. Taken together, these findings suggest DPCPX may prevent the inhibitory effects of bgmATP and 2mSATP via the action of accumulating cAMP as a facilitatory second messenger in the excitation-release mechanisms of the adrenergic nerve terminal. However, DPCPX did not prevent the inhibitory effect of clonidine on the NA release. Furthermore, DPCPX did not increase the spontaneous and EFS-evoked NA release by itself. Therefore, this possibility is ruled out. Probably, DPCPX competes with bgmATP and 2mSATP at the prejunctional inhibitory purinoceptors of the adrenergic nerves in the rat mesenteric artery.
In a previous study, it was demonstrated that both P 1 -and P 2-receptor agonists inhibited the release of NA, and the inhibitory effect was antagonized by a P1-antagonist, 8-sulfophenyl theophylline, in the rat caudal artery (6) and vas deferens (12) . According to the P1-and P2-receptors classification criteria suggested by Burnstock (21) , nucleotides such as ATP and ADP are poor agonists for P1-receptors. In 1984, Stone (22) proposed the existence of unique purinoceptors, which can be classified as neither P1-nor P2-receptors by their sensitivity to various agonists and antagonists. Therefore, we have postulated that the nerve terminal may possess a hybrid purinoceptor for nucleotides and nucleosides that is a type of P3-receptor (23, 24) . Recently, Saitoh and Nakata (25) purified a novel NECA binding protein from rat brain membrane and suggested that the protein is a subtype of a P3-receptor or P3-receptor-like protein.
Studies supporting this idea have been increasing (26, 27) .
In the present study, the inhibitory effects of bgmATP and 2mSATP on the EFS-evoked NA release were blocked by PPADS, a P2-receptor antagonist, but PPADS did not block the inhibitory effects of 2CA and NECA, P1-receptor agonists. This indicates that in the rat mesenteric artery, P 1-receptor agonists and P2-agonists act on separate receptors. P 1-receptor agonists, 2CA and NECA, probably act on A1-adenosine receptor to inhibit NA release as suggested previously (28, 29) . On the other hand, P2-receptor agonists, bgmATP and 2mSATP, are considered to act on DPCPX and PPADS-sensitive prejunctional ATP-receptors to inhibit NA release. As this receptor could not be adequately defined as established purinoceptors (23, 24) , it might be a new type of P2.
In conclusion, the present study showed that a P2-receptor agonist produced a prejunctional inhibition of the release of NA via a P1-antagonist-sensitive mechanism without converting to adenosine. Also, the P2-antagonist sig- nificantly reduced the inhibitory effects of the P2-receptor agonist, but did not affect that of the P1-receptor agonist. These findings indicate that prejunctional purinoceptors mediating an inhibition of the release of NA from adrenergic nerves in the mesenteric artery are P1 (probably A1) and an unidentified purinoceptor that is activated by a P2-receptor agonist and blocked by both P1-and P2-antagonists. To determine further details about purinergic regulation of the adrenergic neurotransmission, more work using a different approach is necessary.
